It is very uncertain whether early warning signs training and treatment as usual changes adverse events: Lost to compared with treatment (very low certainty).
INTERMITTENT (EARLY‐BASED) showed no clear difference in adverse effects: tardive dyskinesia: long term (+26 weeks) as… compared with MAINTENANCE THERAPY (low certainty).
INTERMITTENT (EARLY‐BASED) may leads to higher relapse: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (low certainty).
INTERMITTENT (EARLY‐BASED) probably leads to higher hospitalisation: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (moderate certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with placebo (very low certainty).
Summary of findings table ‐ Cognitive behavioural therapy plus… showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with control (moderate certainty).
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with CBT plus antipsychotics (very low certainty).
Summary of findings table ‐ CBT without antipsychotics showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with no specific treatment (low certainty).
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with antipsychotics (very low certainty).
It is very uncertain whether magnetic seizure therapy plus standard care changes leaving the study early: any reasonassessed by: number of dropouts… compared with electroconvulsive therapy plus standard care (very low certainty).
Group cognitive behavioural therapy for psychosis showed no clear difference in leaving the study early: for any reason – end of treatment compared with standard care (low certainty).
H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).